Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X, Demos M, Gustine J, Chan G, Munshi M, Tsakmaklis N, Chen JG, Kofides A, Sklavenitis-Pistofidis R, Bustoros M, Keezer A, Meid K, Patterson CJ, Sacco A, Roccaro A, Branagan AR, Yang G, Ghobrial IM, Castillo JJ. Treon SP, et al. Among authors: demos m. J Clin Oncol. 2020 Apr 10;38(11):1198-1208. doi: 10.1200/JCO.19.02314. Epub 2020 Feb 21. J Clin Oncol. 2020. PMID: 32083995 Free PMC article. Review.
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
Gustine JN, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ, Xu L. Gustine JN, et al. Among authors: demos mg. Br J Haematol. 2019 Jan;184(2):242-245. doi: 10.1111/bjh.15560. Epub 2018 Sep 5. Br J Haematol. 2019. PMID: 30183082 Free article.
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.
Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, Chan GG, Chen J, Liu X, Munshi M, Gustine J, Meid K, Patterson CJ, Yang G, Dubeau T, Samur MK, Castillo JJ, Anderson KC, Munshi NC, Treon SP. Hunter ZR, et al. Among authors: demos mg. Blood Adv. 2018 Nov 13;2(21):2937-2946. doi: 10.1182/bloodadvances.2018022962. Blood Adv. 2018. PMID: 30401751 Free PMC article.
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Castillo JJ, Xu L, Gustine JN, Keezer A, Meid K, Dubeau TE, Liu X, Demos MG, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Yang G, Hunter ZR, Treon SP. Castillo JJ, et al. Among authors: demos mg. Br J Haematol. 2019 Nov;187(3):356-363. doi: 10.1111/bjh.16088. Epub 2019 Jul 3. Br J Haematol. 2019. PMID: 31267520 Free article.
CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.
Gustine JN, Xu L, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Keezer A, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ. Gustine JN, et al. Among authors: demos mg. Blood Adv. 2019 Oct 8;3(19):2800-2803. doi: 10.1182/bloodadvances.2019000635. Blood Adv. 2019. PMID: 31570491 Free PMC article.
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
Castillo JJ, Gustine JN, Keezer A, Meid K, Flynn CA, Dubeau TE, Chan G, Chen J, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. Castillo JJ, et al. Among authors: demos mg. Am J Hematol. 2020 Apr;95(4):372-378. doi: 10.1002/ajh.25712. Epub 2020 Jan 7. Am J Hematol. 2020. PMID: 31868242 Free article.
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.
Castillo JJ, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. Castillo JJ, et al. Among authors: demos mg. Am J Hematol. 2020 Apr;95(4):E95-E98. doi: 10.1002/ajh.25730. Epub 2020 Jan 23. Am J Hematol. 2020. PMID: 31943341 Free article. No abstract available.
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
Castillo JJ, Itchaki G, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. Castillo JJ, et al. Among authors: demos mg. Leuk Lymphoma. 2020 Jun;61(6):1388-1394. doi: 10.1080/10428194.2020.1719100. Epub 2020 Jan 29. Leuk Lymphoma. 2020. PMID: 31992103
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
Munshi M, Liu X, Chen JG, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Jimenez C, Chan GG, Hunter ZR, Palomba ML, Argyropoulos KV, Meid K, Keezer A, Gustine J, Dubeau T, Castillo JJ, Patterson CJ, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. Munshi M, et al. Among authors: demos mg. Blood Cancer J. 2020 Jan 31;10(1):12. doi: 10.1038/s41408-020-0277-6. Blood Cancer J. 2020. PMID: 32005797 Free PMC article.
88 results